BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

868 related articles for article (PubMed ID: 29634284)

  • 1. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
    Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
    Tsoyi K; Liang X; De Rossi G; Ryter SW; Xiong K; Chu SG; Liu X; Ith B; Celada LJ; Romero F; Robertson MJ; Esposito AJ; Poli S; El-Chemaly S; Perrella MA; Shi Y; Whiteford J; Rosas IO
    Am J Respir Crit Care Med; 2021 Aug; 204(3):312-325. PubMed ID: 33784491
    [No Abstract]   [Full Text] [Related]  

  • 3. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
    Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
    PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis.
    Tzouvelekis A; Yu G; Lino Cardenas CL; Herazo-Maya JD; Wang R; Woolard T; Zhang Y; Sakamoto K; Lee H; Yi JS; DeIuliis G; Xylourgidis N; Ahangari F; Lee PJ; Aidinis V; Herzog EL; Homer R; Bennett AM; Kaminski N
    Am J Respir Crit Care Med; 2017 Feb; 195(4):500-514. PubMed ID: 27736153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quercetin Enhances Ligand-induced Apoptosis in Senescent Idiopathic Pulmonary Fibrosis Fibroblasts and Reduces Lung Fibrosis In Vivo.
    Hohmann MS; Habiel DM; Coelho AL; Verri WA; Hogaboam CM
    Am J Respir Cell Mol Biol; 2019 Jan; 60(1):28-40. PubMed ID: 30109946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the AXL Receptor in Combating Smoking-related Pulmonary Fibrosis.
    Yang DC; Gu S; Li JM; Hsu SW; Chen SJ; Chang WH; Chen CH
    Am J Respir Cell Mol Biol; 2021 Jun; 64(6):734-746. PubMed ID: 33730527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation.
    Bárcena C; Stefanovic M; Tutusaus A; Joannas L; Menéndez A; García-Ruiz C; Sancho-Bru P; Marí M; Caballeria J; Rothlin CV; Fernández-Checa JC; de Frutos PG; Morales A
    J Hepatol; 2015 Sep; 63(3):670-8. PubMed ID: 25908269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.
    Ghebremariam YT; Cooke JP; Gerhart W; Griego C; Brower JB; Doyle-Eisele M; Moeller BC; Zhou Q; Ho L; de Andrade J; Raghu G; Peterson L; Rivera A; Rosen GD
    J Transl Med; 2015 Aug; 13():249. PubMed ID: 26231702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Tyrosine Phosphatase-N13 Promotes Myofibroblast Resistance to Apoptosis in Idiopathic Pulmonary Fibrosis.
    Bamberg A; Redente EF; Groshong SD; Tuder RM; Cool CD; Keith RC; Edelman BL; Black BP; Cosgrove GP; Wynes MW; Curran-Everett D; De Langhe S; Ortiz LA; Thorburn A; Riches DWH
    Am J Respir Crit Care Med; 2018 Oct; 198(7):914-927. PubMed ID: 29727583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state.
    Caporarello N; Meridew JA; Jones DL; Tan Q; Haak AJ; Choi KM; Manlove LJ; Prakash YS; Tschumperlin DJ; Ligresti G
    Thorax; 2019 Aug; 74(8):749-760. PubMed ID: 31182654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
    Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
    Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplified canonical transforming growth factor-β signalling
    Sibinska Z; Tian X; Korfei M; Kojonazarov B; Kolb JS; Klepetko W; Kosanovic D; Wygrecka M; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Guenther A; Schermuly RT
    Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 28182573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP1/Twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF.
    Chen Y; Zhao X; Sun J; Su W; Zhang L; Li Y; Liu Y; Zhang L; Lu Y; Shan H; Liang H
    Cell Death Differ; 2019 Sep; 26(9):1832-1844. PubMed ID: 30644438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-PKcs modulates progenitor cell proliferation and fibroblast senescence in idiopathic pulmonary fibrosis.
    Habiel DM; Hohmann MS; Espindola MS; Coelho AL; Jones I; Jones H; Carnibella R; Pinar I; Werdiger F; Hogaboam CM
    BMC Pulm Med; 2019 Aug; 19(1):165. PubMed ID: 31464599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis.
    Barnes JW; Duncan D; Helton S; Hutcheson S; Kurundkar D; Logsdon NJ; Locy M; Garth J; Denson R; Farver C; Vo HT; King G; Kentrup D; Faul C; Kulkarni T; De Andrade JA; Yu Z; Matalon S; Thannickal VJ; Krick S
    Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L141-L154. PubMed ID: 31042083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury.
    Smith MR; Gangireddy SR; Narala VR; Hogaboam CM; Standiford TJ; Christensen PJ; Kondapi AK; Reddy RC
    Am J Physiol Lung Cell Mol Physiol; 2010 May; 298(5):L616-25. PubMed ID: 20061443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long Noncoding RNA FENDRR Exhibits Antifibrotic Activity in Pulmonary Fibrosis.
    Huang C; Liang Y; Zeng X; Yang X; Xu D; Gou X; Sathiaseelan R; Senavirathna LK; Wang P; Liu L
    Am J Respir Cell Mol Biol; 2020 Apr; 62(4):440-453. PubMed ID: 31697569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of α
    Decaris ML; Schaub JR; Chen C; Cha J; Lee GG; Rexhepaj M; Ho SS; Rao V; Marlow MM; Kotak P; Budi EH; Hooi L; Wu J; Fridlib M; Martin SP; Huang S; Chen M; Muñoz M; Hom TF; Wolters PJ; Desai TJ; Rock F; Leftheris K; Morgans DJ; Lepist EI; Andre P; Lefebvre EA; Turner SM
    Respir Res; 2021 Oct; 22(1):265. PubMed ID: 34666752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
    Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
    Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.